Oxycodone and morphine are more likely to contain messaging on package inserts describing safe storage and disposal methods compared with other commonly used and misused opioid analgesics.
The 7 opioids included for analysis were oxycodone, hydrocodone, morphine, hydromorphone, oxymorphone, tapentadol, and tramadol.
A new tamper-resistant formulation of controlled-release oxycodone was not found to reduce opioid use or harm at the population level.
An investigational vaccine may represent an effective treatment strategy for oxycodone abuse and may help reduce oxycodone overdose severity.
The use of oxycodone/naloxone prolonged-release tablets (OXN PR) can provide significant relief for patients who suffer from moderate to severe chronic pain and opioid-induced constipation.
An abuse liability assessment was conducted to determine the abuse potential and pharmacokinetics of extended-release vs immediate-release oxycodone.
Abuse-deterrent extended-release oxycodone (Xtampza® ER; Collegium Pharmaceutical) provided adequate pain relief for patients with chronic low back pain who were previously receiving immediate-release oxycodone.
Administration of abuse-deterrent formulations of immediate-release oxycodone and extended-release morphine leads to slower and lower absorption rates in nondependent recreational drug users compared with standard oxycodone and morphine formulations.
In hospitalized patients, tramadol use was shown to be associated with hypoglycemia.
About 20% of U.S. bariatric surgery patients are still using prescription opioids 7 years later.
A prescription weight-loss drug reduced the urge to use opiates like oxycodone.
Drug overdose deaths have nearly tripled in the United States since 1999, with the largest increases seen for whites and middle-aged Americans.
Chronic pain patients being treated with certain opioid and non-opioid medications had significantly lower serum concentrations of free testosterone and free estradiol.
The article reviews the epidemiology, clinical features, outcomes, prevention strategies, risk identification and management NAS.
The benefit-risk profile of oxycodone/naloxone was found to be noninferior compared to tapentadol, and oxycodone/naloxone demonstrated superior analgesic efficacy.
Clinical Pain Advisor Articles
- Cannabis Use High in Migraine
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Percutaneous Electrolysis May Be Useful Adjunct for Subacromial Pain Syndrome
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Targeted Educational Intervention Helped Reduce Opioid Exposure in Adult Inpatients
- Systematic Cross-Checking May Reduce Medical Errors in Emergency Departments
- Corticosteroid Plus Lidocaine Injections Do Not Alleviate Pain in Central Lumbar Spinal Stenosis
- Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis